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Abstract
Endothelial dysfunction is considered one of the 
etiological factors of inflammatory bowel disease 
(IBD). An inflammatory process leads to functional 
and structural changes in the vascular endothelium. 
An increase of leukocyte adhesiveness and leukocyte 
diapedesis, as well as an increased vascular smooth 
muscle tone and procoagulant activity is observed. 
Structural changes of the vascular endothelium 
comprise as well capillary and venule remodeling 
and proliferation of endothelial cells. Hypoxia in the 
inflammatory area stimulates angiogenesis by up-
regulation of vascular endothelial growth factor, 
fibroblast growth factor and tumor necrosis factor-α. 
Inflammatory mediators also alter the lymphatic 
vessel function and impair lymph flow, exacerbating 
tissue edema and accumulation of dead cells and 
bacteria. The endothelial dysfunction might be 
diagnosed by the use of two main methods: physical 
and biochemical. Physical methods are based on the 
assessment of large arteries vasodilatation in response 
to an increased flow and receptors stimulation. Flow-
mediated vasodilatation (FMD) is the method that is 
the most widely used; however, it is less sensitive in 
detecting early changes of the endothelium function. 
Most of the studies demonstrated a decrease of 
FMD in IBD patients but no changes in the carotic 
intima-media thickness. Biochemical methods of 
detecting the endothelial dysfunction are based on the 
assessment of the synthesis of compounds produced 
both by the normal and damaged endothelium. The 
endothelial dysfunction is considered an initial step 
in the pathogenesis of atherosclerosis in the general 
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population. In IBD patients, the risk of cardiovascular 
diseases is controversial. Large, prospective studies are 
needed to establish the role of particular medications 
or dietary elements in the endothelial dysfunction 
as well to determine the real risk of cardiovascular 
diseases.
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thelial dysfunction; Inflammatory bowel diseases; 
Inflammation; Microvasculature
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Core tip: Endothelial dysfunction seems to play an 
important role in the pathogenesis of inflammatory 
bowel disease (IBD). Inflammatory process leads 
to functional and structural changes in the vascular 
endothelium and in consequence its activation. It may 
contribute to cardiovascular complications, however, in 
IBD patients, the risk of cardiovascular disease is still 
controversial. Some of immunomodulatory medications 
used in IBD treatment may decrease the risk of endo-
thelial dysfunction. In this review article, we present 
the role of the endothelium in the inflammatory pro-
cess, diagnostic methods of its dysfunction and current 
knowledge of the cardiovascular disease risk in IBD.
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INTRODUCTION
Inflammatory bowel disease (IBD) has a multifactorial 
etiology that has not been fully elucidated. Patients 
with IBD are genetically predisposed to pathological 
interactions between intestinal microflora and the 
immunological system[1]. Changes in the balance 
between regulatory and inflammatory cytokines 
lead to maintenance of the inflammatory process[2]. 
Dysfunction of the endothelium has also been con­
sidered an etiological factor.
The endothelium is a highly specialized, single­
layered epithelium that lines internal surfaces of blood 
and lymph vessels and cardiac valves[3,4]. It plays 
a significant role in tissue flow, blood coagulation, 
regulation of substance transport across vascular walls, 
and regulation of the number and type of leukocytes 
migrating across vascular walls[3,5]. Endothelial 
cells are characterized by high metabolic activity, 
basement membrane­producing elements, intercellular 
components, and numerous substances that regulate 
blood vessel function, such as nitric oxide (NO), 
endothelin 1, prostacyclin 2, von Willebrand factor 
(vWF), and cellular adhesion molecules (CAMs)[3,6] 
(Table 1). Under physiological conditions, the 
endothelium has dilating effect on vessels, prevents 
their excessive permeability, and prevents adhesion 
and aggregation of blood platelets and leukocytes. 
It also regulates fibrinolysis and the coagulation 
pathway[4,7] (Figures 1 and 2).
NO is a key mediator secreted by the endothelium 
and is produced from L­arginine by endothelial nitric 
oxide synthase (eNOS)[8]. It is released from the 
endothelium in response to shearing forces applied 
to the vascular wall[9]. It acts by increasing the 
concentration of cyclic guanosine monophosphate, 
which has a vasodilatory effect, and also inhibits the 
expression of cytokines, chemokines, and leukocyte 
adhesion substances, inhibits blood platelet adhesion 
and aggregation, and limits the proliferation of smooth 
muscle cells in the vascular wall[6,9]. Endothelium­
derived hyperpolarizing factor also has a vasodilatory 
effect, whereas a vasoconstrictive effect is exhibited 
by endothelin 1 and endothelium­derived contracting 
factor.
PaThOgeNesIs
Vascular endothelium
Endothelial dysfunction is “an imbalance between 
vasodilatating and vasoconstricting substances 
produced by (or acting on) endothelial cells”[10]. 
Inflammation leads to functional and structural 
changes in vascular endothelium and its activation 
(Figure 3). These changes initially include increased 
leukocyte adhesiveness, leukocyte diapedesis, and 
vascular smooth muscle tone and procoagulant 
activity[5,11]. Activation of endothelial cells is promoted 
by the interactions between integrins and chemokine 
receptors with endothelial and mucosal ligands, the 
CAM superfamily, and chemokines[12,13]. Activated 
endothelium expresses CAMs and chemokines, 
which promote the recruitment of leukocytes[14,15]. 
Adhesion is the most important process determining 
which leukocytes migrate to tissues[16]. The three 
main classes of CAMs are selectins, integrins, and 
the immunoglobulin CAM superfamily, including 
intercellular adhesion molecule­1 (ICAM­1), ICAM­2, 
and vascular cell adhesion molecule­1 (VCAM­1))[17]. 
This process is mainly mediated by leukocyte CD11a/
CD18 binding to ICAM­1 in the gut or by α4­β1 or 
α4­β7 binding to VCAM­1 and mucosal addressin cell 
adhesion molecule­1 (MAdCAM­1)[12].
Cultures of human intestinal microvascular 
endothelial cells (HIMECs) have revealed unique 
leukocyte adhesion and growth patterns[18]. Significant 
changes, particularly an enhanced capacity to 
adhere to leukocytes, occur in chronically inflamed 
microvessels of patients with IBD compared to 
vessels from healthy controls and patients without 
IBD[5]. Microvascular expression of ICAM­1 and 
VCAM­1 is upregulated in patients with IBD[14,16]. 
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Increased MAdCAM­1 expression is also observed, 
which increases recruitment of α4 integrin­expressing 
leukocytes[19]. Vowinkel et al[20] demonstrated a 
significant increase in endothelial expression of CD40, 
resulting in increased recruitment of leukocytes.
The risk for hyperhomocysteinemia is significantly 
higher in patients with IBD than in those without the 
disease[21,22]. HIMECs are activated by homocysteine 
alone or homocysteine combined with tumor necrosis 
factor­α (TNF­α), leading to enhanced VCAM­1 expre­
ssion, increased production of monocyte chemotactic 
protein­1, and phosphorylation of p38 mitogen­
activated protein kinase[16,23].
Decreased NO production occurs in patients with 
IBD, which may be caused by increased arginase 
activity, an enzyme that competes with NOS, and a 
lack of inducible NOS mRNA expression[16,24,25]. Vascular 
endothelium is also a TNF­α target[11]. Binding of TNF­α 
to the TNF receptor leads to diminished eNOS protein 
expression and suppresses eNOS activity, which 
prevents degradation of asymmetric dimethylarginine 
(ADMA), an endogenous eNOS inhibitor[11,26]. Reactive 
oxygen species are produced in the inflamed area, 
which generate oxidative stress in vWF molecules. 
This process inhibits cleavage of vWF molecules by 
disintegrin and metalloproteinase with thrombospondin 
motif­13 and contributes to the creation of ultra­large 
vWF multimers leading to microvascular thrombosis in 
patients with IBD[13,17,27].
Structural changes in vascular endothelium include 
capillary and venule remodeling and proliferation 
of endothelial cells[28]. Angiogenesis is a crucial 
process that sustains chronic inflammation in the 
gastrointestinal tract. Numerous inflammatory cell 
types, including macrophages, lymphocytes, mast 
cells, and fibroblasts, produce angiogenic factors and 
promote pathological angiogenesis in inflammatory 
tissues[16,29]. Hypoxia in the inflamed area stimulates 
angiogenesis by upregulating vascular endothelial 
growth factor (VEGF), fibroblast growth factor, and 
TNF­α[29]. Rutella et al[30] suggested that inflamed 
HIMECs recruit platelets to produce higher levels of 
pro­angiogenic VEGF­A and CD40 ligand (CD40L) in 
patients with active ulcerative colitis (UC) and Crohn’s 
disease (CD)[30].
The CD40­CD40L pathway has a dual role, 
directly stimulating mucosal angiogenesis and acti­
vating CD40L­expressing T cells, which in turn 
stimulates intestinal fibroblasts to release angiogenic 
cytokines[31]. CD40 is upregulated by several cell types 
in patients with IBD, including antigen­presenting 
cells, monocytes, and endothelial cells. CD40L is 
overexpressed by T cells and platelets, and plasma 
CD40L levels are particularly high in patients with 
active IBD[31,32]. The CD40­CD40L pathway promotes 
mucosal inflammation and triggers increased production 
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Table 1  Factors released by endothelium
Factors regulating vascular tension Factors regulating angiogenesis and 
cells proliferation
Factors regulating coagulation 
and fibrinolysis
Factors regulating inflammatory process
Vasodilating effect Vasoconstricting 
effect
Inhibition of 
proliferation
Stimulation of 
proliferation
Anticoagulant 
effect
Prothrombotic 
effect
Anti-inflammatory 
effect
Proinflammatory 
effect
Adrenomedullin 
(ADM)
Angiotensin Ⅱ 
(AT Ⅱ)
Extracellular 
proteases 
inhibitors
Adenosine (Ado) Antithrombin 
Ⅲ (AT Ⅲ)
ET-1 NO Adhesion molecules
Bradykinin (BK) Endothelin-1 
(ET-1)
NO AT Ⅱ Heparan sulfate PAF PGI2 Chemokines
C-type natriuretic 
peptide (CNP)
Platelet-
activating factor 
(PAF)
PGI2 ET-1 NO Plasminogen 
activator 
inhibitor type 1 
(PAI-1)
Cytokines
Endothelium-derived 
hyperpolarizing 
factor (EDHF)
Prostaglandin H2 
(PGH2)
Transforming 
growth factor-β 
(TGF-β)
Heparan sulfate PGI2 ROS Nuclear factor 
kappa-light-
chain-enhancer of 
activated B cells 
(NF-kB)
Nitric oxide (NO) Thromboxane A2 
(TXA2)
Insulin-like 
growth factor 1 
(IGF-1)
Protein C (PC) Tissue factor 
(TF)
Prostacyclin (PGI2) Reactive oxygen 
species (ROS)
Interleukins (Il) Tissue factor 
pathway 
inhibitor (TFPI)
TXA2
ROS Tissue-type 
plasminogen 
activator (t-PA)
Von 
Willebrand 
factor (VWF)
Vascular 
endothelial 
growth factor 
(VEGF)
Urokinase 
plasminogen 
activator (uPA)
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of various cytokines and cell adhesion molecules[31]. 
CD40 binding stimulates the production of TNF­α, and 
TNF­α increases CD40 expression[32].
Intestinal endothelium is also involved in innate 
immunity by expressing toll­like receptors (TLRs), 
which increase the expression of proinflammatory 
genes and promote leukocyte chemotaxis, pha­
gocytosis, and cytotoxicity as a second­line defense 
against bacterial entry[33]. Expression of TLRs on 
vascular endothelial cells is upregulated by vascular 
inflammation, as well as by lipopolysaccharide. 
Endothelial cells detect both extracellular and 
intracellular microbial invaders through TLRs and 
activate the nucleotide oligomerization domain family 
of proteins[34]. Activated TLRs upregulate endothelial 
leukocyte adhesion molecules, increasing leukocyte 
transmigration[35].
Tolstanova et al[36] demonstrated that damage 
to endothelium and increased vascular permeability 
lead to hypoxia in four UC animal models, which 
increases the levels of oxygen­derived toxic free 
radicals and induces epithelial cell injury followed by 
the development of erosions und ulcerations. Genetic 
predisposition, activation of the VEGF gene, and 
activation of TLR2 by oxidation stress are responsible 
for increased endothelial microvascular permeability in 
Figure 2  Procoagulant activity of endothelium. PAI-1: Plasminogen activator inhibitor type 1; t-PA: Tissue-type plasminogen activator; TXA2: Thromboxane A2; TF: 
Tissue factor; VWF: von Willebrand factor.
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Figure 1  Anticoagulant activity of endothelium. NO: Nitric oxide; PGI2: Prostacyclin; PC: Protein C; APC: Activated protein C; Ⅴ, Ⅷ: Coagulation factors; TFPI: 
Tissue factor pathway inhibitor; t-PA: Tissue-type plasminogen activator.
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patients with UC[36].
Lymphatic endothelium
The lymphatic vessels are responsible for intestinal 
lymphatic transport and elimination of accumulated 
fluid, inflammatory cells, and mediators. However, 
inflammatory mediators released alter lymphatic vessel 
function and impair lymph flow in patients with IBD, 
which exacerbates tissue edema and the accumulation 
of dead cells and bacteria. Lymphangiogenesis 
is mediated by binding of the lymphatic vascular 
endothelial selective growth factors VEGF­C and 
VEGF­D/VEGF receptor­3[37].
Lymphatic obstruction, submucosal edema, and 
extended lymphangiogenesis are observed in patients 
with IBD[13,16]. Rahier et al[38] reported that lymphatic 
density increases significantly in patients with CD 
and UC in both inflamed and non­inflamed intestinal 
mucosa. Tonelli et al[39] demonstrated a correlation 
between parietal wall thickness and the severity of 
changes in lymphatic drainage in patients with IBD 
and stenosis, and reported that these abnormalities 
disappeared after strictureplasty. It remains unclear 
whether the impaired lymphatic function in patients 
with IBD is a consequence of inflammation or a 
preceding lymphangitis­like event[40].
DIagNOsTIC meThODs Of DeTeCTINg 
eNDOThelIal DysfUNCTION
Endothelial dysfunction is diagnosed using physical 
and biochemical methods. Physical methods are 
based on assessing vasodilation in large arteries in 
response to increased flow and receptor stimulation, 
mainly acetylcholine[3,34]. The most popular non­
invasive procedures are presented in Table 2. Among 
these methods, flow­mediated vasodilation (FMD) 
is the most widely used and the most sensitive[11,41]. 
However, these methods may not accurately reflect 
endothelial function in the microcirculation and are 
less sensitive for detecting early changes in endothelial 
function[11,42].
The biochemical methods used to detect endothelial 
dysfunction are based on assessing the synthesis 
of compounds produced by normal and damaged 
endothelium. Numerous substances are released by 
abnormally activated endothelium (Table 2)[11,43].
Endothelial activity in patients with IBD has been 
evaluated by physical and biochemical methods. 
Kocaman et al[44] reported that both endothelial­
dependent and endothelial­independent dilation are 
significantly worse in patients with severe or moderate 
UC than in controls, and that endothelial dysfunction 
is associated with activity­related extra­intestinal 
complications.
Roifman et al[42] assessed endothelial dysfunction 
and found that 48 patients with UC and CD had 
lower pulse arterial tonometry values and shear 
stress reactive hyperemia compared to controls, 
which indicates endothelial dysfunction. However, no 
association was detected between clinical features such 
as disease duration, underlying therapy, or disease 
activity. Theocharidou et al[45] reported that carotid 
intima­media thickness (cIMT) increases significantly in 
patients with UC and CD but lacks an association with 
clinical disease activity. Similarly, Aloi et al[46] found an 
increase in cIMT and a decrease in FMD in pediatric 
patients. Zanoli et al[47] demonstrated that arterial 
stiffness increases in patients with IBD independently 
of conventional cardiovascular risk factors and that 
carotid­radial pulse wave velocity (PWV) is positively 
correlated with disease duration. Arterial stiffness 
decreases following immunomodulatory therapy 
Cibor D et al . Endothelium dysfunction in IBD
Figure 3  Inflammatory activation of endothelium. TNF: Tumour necrosis factor; IL: Interleukin.
Neutrophil Monocyte Lymphocyte
NF-kB
Endothelium
Proinflammatory cytokines and chemokines:
IL-1B, IL-6, IL-8, TNF-α, MCP-1
Table 2  Methods of endothelium dysfunction assessment
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Proteins activated by normal and activated endothelium Cell-based methods
      Angiopoietin-1 Circulating angiogenic cells
      Angiopoietin-2 Endothelial progenitor cells
      Asymmetric dimethylarginine (ADMA) Endothelial microparticles
      Disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS13)
      Intercellular adhesion molecule-1 (CAM-1)
      Plasminogen-activator inhibitor (PAI-1)
      Selectins P and E
      Tissue plasminogen activator (t-PA)
      Thrombomodulin
      Vascular adhesion molecule-1 (VCAM-1)
      Vascular endothelial growth factor (VEGF)
      von Willebrand factor (vWF)
Non-invasive physical methods
      Carotis intima-media thickness (cIMT)
      Flow mediated dilatation (FMD)
      Pulse arterial tonometry (PAT)
      Pulse wave analysis (PWA)
      Pulse wave velocity (PWV)
      Reactive hyperaemia index (RHI)
Cibor D et al . Endothelium dysfunction in IBD
(steroids and azathioprine or anti­TNF­α)[48]. Several 
studies have reported no differences in cIMT values 
in patients with IBD[49­52]. Ozturk et al[49] measured 
carotid femoral PWV, cIMT, and FMD in a group of 
patients with IBD without additional cardiovascular 
risks. They did not find any changes in cIMT, but 
they reported a significantly lower FMD and higher 
carotid femoral PWV. Similarly, a Korean study on 38 
patients with IBD did not show an increase in cIMT 
compared to healthy controls. Disease severity was 
not correlated with cIMT but a positive correlation was 
detected with disease duration[50]. Kayahan et al[51] and 
Broide et al[52] reported no differences in cIMT, but the 
latter study reported a significantly impaired FMD in 
patients with IBD. Petr et al[53] evaluated the reactive 
hyperemia index (RHI) and E­selectin and ADMA levels 
in 21 patients with CD and reported a decrease in RHI 
but increases in E­selectin and ADMA levels.
A few studies have assessed the levels of endo­
thelial dysfunction biomarkers in serum of patients 
with IBD and have provided controversial data. Some 
studies have reported an increase in VEGF level[54,55]. 
In another study, no difference in ICAM­1 or E­selectin 
expression was observed between patients with active 
UC and inactive CD[56]. In contrast, Adamska et al[57] 
reported a significant increase in E­selectin expression 
in patients with active CD compared to patients in 
remission. Similarly, Goggins et al[58] demonstrated an 
increase in levels of ICAM­1 and E­selectin in serum of 
patients with IBD but C­reactive protein (CRP) was a 
better indicator of disease activity. Another study found 
increased ICAM­1 levels in patients with IBD compared 
to healthy controls[55]. Magro et al[59] demonstrated 
that levels of P­selectin, E­selectin, VCAM, ICAM, VEGF, 
and angiogenin in serrum are significantly lower in 
patients with inactive CD than in controls, suggesting 
dysfunction in the angiogenic process and wound 
repair. Lower levels of VEGF and angiogenin have been 
demonstrated in patients with inactive IBD compared 
to those with active disease[60].
ImPlICaTIONs
Risk of cardiovascular complications
Chronic systemic inflammatory diseases are asso­
ciated with accelerated atherosclerosis, a higher 
rate of cardiovascular disease (CVD), and increased 
morbidity and mortality compared to the general 
population[11,61­63]. Inflammatory mediators, such as 
CRP, TNF­α, interleukin (IL)­6, IL­18, and CD40L, 
are involved in the pathogenesis of inflammation 
and atherosclerosis[64,65]. Endothelial dysfunction is 
considered the initial step in the pathogenesis of 
atherosclerosis in the general population and may be a 
marker for future risk of cardiovascular events[66].
The risk for CVD in patients with IBD is contro­
versial. Some studies have demonstrated an increased 
risk for CVD in these patients[66­68], whereas others 
have provided no evidence for an increased risk of 
mortality due to CVD[69­71]. Ruisi et al[72] found no 
increased risk for CVD in patients with IBD without 
traditional CVD risk factors after a 2­year follow­
up. A meta­analysis performed by Fumery et al[73] 
and composed of 33 observational studies showed 
a higher risk for ischemic heart disease and arterial 
thromboembolism in patients with IBD but no 
increased risk for cardiovascular mortality. In addition, 
Singh et al[74] reported a 19% higher risk of CVD 
in patients with IBD and a modest increased risk 
for cardiovascular morbidity (from cerebrovascular 
accidents and ischemic heart disease), mostly in 
female patients[74]. Kristensen et al[75] performed 
a population­based study and demonstrated an 
increased risk for myocardial infarction in patients with 
IBD during flare­ups and during persistent disease 
activity, but not in patients in remission[76].
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Coronary flow reserve is impaired in patients 
with IBD, suggesting dysfunction in coronary micro­
circulation[76].
Fan et al[77] concluded that traditional risk factors, 
such as age, systolic blood pressure, body mass 
index, diabetes, and triglycerides, rather than 
inflammatory markers, are major predictors of arterial 
stiffness in patients with an inflammatory disease. 
In contrast, Ozturk et al[49] suggested that patients 
with IBD without traditional cardiovascular risk factors 
have higher risks for endothelial dysfunction and 
atherosclerosis.
Some studies have suggested that patients with 
IBD, particularly those with CD, exhibit low levels of 
total cholesterol and low­density lipoprotein (LDL)[78]. 
However, Sappati Biyyani et al[79] reported lower total 
cholesterol but higher LDL and lower high­density 
lipoprotein levels in patients with IBD in a large 
retrospective study. Changes in the lipid profile do 
not depend on disease activity[77]. Despite a lower 
incidence of traditional CVD risk factors in patients 
with IBD, these patients are diagnosed with coronary 
artery disease at a younger age[67,80]. It is important 
to emphasize that some patients with CD are tobacco 
smokers, which could also contribute to enhanced 
endothelial damage[81]. These findings indicate that 
large prospective studies are needed to determine the 
actual risks for CVD in patients with IBD.
Pharmacological interventions and endothelial function
Pharmacological agents directed against TNF­α­
mediated inflammation may decrease the risk for 
endothelial dysfunction and CVD in patients with IBD. 
Some studies that have addressed rheumatoid arthritis 
have demonstrated decreased levels of endothelial 
dysfunction biomarkers in plasma after anti­TNF­α 
therapy[11]. Other studies have shown improved 
endothelium­dependent vasodilation in patients with 
inflammatory diseases, including rheumatoid arthritis, 
spondyloarthritis, psoriasis, and IBD after initiating 
anti­TNF­α therapy[11,48,82]. However, whether this effect 
is permanent or transient remains controversial[11]. 
Arijs et al[83] demonstrated that inflammatory cells 
from the intestinal lamina propria disappear after an 
infliximab infusion and that previously upregulated 
cell adhesion molecules are restored. Some authors 
have suggested that anti­TNF­α antibodies inhibit 
angiogenesis in patients with IBD[84,85]. Danese et al[32] 
showed that anti­TNF­α downregulates the CD40/
CD40L pathway.
The effects of TNF­α on the cardiovascular 
system could be both beneficial and harmful due to 
concentration­related differences in activation of 
different receptors[63,86].
Data regarding corticosteroids are controversial 
as well. However, a systematic review of studies 
that assessed steroid administration in patients with 
rheumatoid arthritis did not report any effects of 
steroid use on endothelial function[87].
At the same time, it is probable that methotrexate 
improves endothelial­dependent vasodilation in 
patients with rheumatoid arthritis[62]. A weekly low 
dose of methotrexate reduces disease­associated 
cardiovascular mortality. Thornton et al[88] suggested 
that methotrexate induces cytoprotective genes by 
activating adenosine monophosphate protein kinase­
cyclic AMP response element binding protein signaling, 
which prevents CVD.
In vitro studies have indicated that cyclosporine 
induces increased activation of endothelial cells[89]. 
However, some evidence suggests that cyclosporine 
A inhibits angiogenesis targeting VEGF­A[84,90]. At 
the same time, azathioprine and its metabolite, 
6­mercaptopurine, may play a protective role against 
the activation of endothelial cells[91].
New therapeutic options for patients with IBD 
include anti­adhesion molecules, such as vedolizumab, 
etrolizumab, and PF­00547659[92]. Vedolizumab targets 
α4­β7 integrins and blocks interactions between α4­β7 
integrins and MAdCAM­1. Etrolizumab targets the β7 
subunit, and PF­00547659 is a monoclonal antibody 
against MAdCAM­1[92]. Anti­chemokine receptor 
CCR 9 interferes with the activation of inflammatory 
cells in the intestine. Other medications, such as 
laquinimod and tofacitinib, reduce the synthesis of pro­
inflammatory cytokines[92].
As the lymphatic endothelium seems to play 
an adaptive role in the inflammation that occurs in 
patients with IBD, the inflammatory process may also 
be affected by stimulating lymphatic vessel functions, 
such as drainage and clearance of bacterial antigens, 
together with adaptive immunity[37]. D’Alessio et 
al[37] demonstrated that adenoviral induction of the 
prolymphangiogenic factor VEGF­C in two different 
animal models significantly prevents the development 
of acute and chronic colitis, which supports the 
potential use of lymphangiogenic growth factors as a 
novel therapeutic approach[37].
Improved endothelial function may also be achieved 
by increasing NO availability, as antioxidants affect 
the decrease in NO breakdown. Dietary components, 
such as vitamins C and E, have potential benefits 
on endothelial function and could prevent CVD[93]. 
Recent studies provide no evidence for a supportive 
role of vitamin D in endothelial function[94]. Ibrahim 
et al[95] showed that treatment with long­chain n­3 
polyunsaturated fatty acid decreases the expression 
of adhesion molecules in endothelial cells and has a 
potential anti­angiogenic role in animal models and in 
vitro.
CONClUsION
Endothelial dysfunction plays a pivotal role in the 
development of IBD. Some immunomodulatory 
medications used to treat IBD affect endothelial 
function; however, large studies on the interactions 
between the gut microvasculature, cytokines, 
Cibor D et al . Endothelium dysfunction in IBD
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chemokines, cell adhesion molecules, inflammatory 
growth factors, and platelets are needed to create new 
therapeutic strategies for patients with IBD.
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